QuAC | CEHTRA

Are you dealing with Quaternary Ammonium Compounds?

We have a solution that will save you
time, cost and resources for your dossier preparation

Introducing

An umbrella interest group to cover all Quaternary Ammonium Compounds (QUATs) and PT Combinations

What is QuAC?

The active substances Didecyldimethylammonium chloride (DDAC – CAS 7173-51-5) and Alkyl (C12-16) dimethylbenzyl ammonium chloride (ADBAC/BKC (C12-16) – CAS 68424-85-1) will be approved for PT1 and PT2 throughout 2024 and 2025 and, at CEHTRA, we’ve been working over the past months in an innovative regulatory approach that will help you deliver successful BPR dossiers saving time, resources and cost.

QuAC Strategy

CEHTRA proposal is based on both: companies’ main interests and our experience dealing with Biocidal Products Families (BPF) within the new guidance framework.

BPR - Article 3(1)(s) specifies that a group of biocidal products having:

(a) Similar uses;

(b) The same active substances,

(d) Similar levels of risk and efficacy

Can be grouped in a Biocidal Product Family (BPF) BUT the latest guidance (CA-July19-Doc4.2-Final_rev2) introduces additional restrictions on similarity requirements that makes it more difficult to build a BPF, especially when trying to group products from different companies. The solution lies in simplifying and reducing differentiation in formulations.

On the other hand, companies prioritize endowing their products with specific performance characteristics that will make them stand out at market level.

At CEHTRA we’ve design a proposal with the legal support of Steptoe, that differs from conventional consortia and where you will find :

One-stop-shop - Cover all the Quats (Combinations between them, different PTs and Use)
Full control - Your are the owner of your dossier and regulatory strategy
Flexibility - You take the lead, we adapt (no need to contract us for the full dossier)
Cost rationalization - Easy and transparent approach
Confidentiality - No need to share sensitive information